BRONCHIECTASIS WITH PSEUDOMONAS AERUGINOSA COLONIZATION
Clinical trials for BRONCHIECTASIS WITH PSEUDOMONAS AERUGINOSA COLONIZATION explained in plain language.
Never miss a new study
Get alerted when new BRONCHIECTASIS WITH PSEUDOMONAS AERUGINOSA COLONIZATION trials appear
Sign up with your email to follow new studies for BRONCHIECTASIS WITH PSEUDOMONAS AERUGINOSA COLONIZATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New antibody aims to cut lung attacks in bronchiectasis patients
Disease control Recruiting nowThis study tests an experimental drug called AZD0292 in 435 people aged 12 and older who have bronchiectasis and a long-term lung infection with Pseudomonas aeruginosa. The goal is to see if the drug can reduce the number of moderate-to-severe lung flare-ups compared to a placebo…
Matched conditions: BRONCHIECTASIS WITH PSEUDOMONAS AERUGINOSA COLONIZATION
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New drug CTX-187 takes aim at stubborn bacterial infections
Disease control Recruiting nowThis first-in-human trial tests an experimental drug called CTX-187 for safety and tolerability. It starts with healthy volunteers to assess single and multiple doses, then moves to patients with bronchiectasis who have a chronic Pseudomonas infection. The goal is to see if the d…
Matched conditions: BRONCHIECTASIS WITH PSEUDOMONAS AERUGINOSA COLONIZATION
Phase: PHASE1 • Sponsor: Centauri Therapeutics Limited • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC